Literature DB >> 8502282

Pathogenesis and treatment of gallstones.

A F Hofmann, A Amelsberg, E vanSonnenberg.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1993        PMID： 8502282

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

Review 1.  Targets for current pharmacologic therapy in cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q H Wang; Helen H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Gastroenterol Clin North Am       Date:  2010-06       Impact factor: 3.806

2.  Decreased SCF/c-kit signaling pathway contributes to loss of interstitial cells of Cajal in gallstone disease.

Authors:  Yu-Yan Tan; Zhen-Ling Ji; Gang Zhao; Jia-Rui Jiang; Dong Wang; Jing-Min Wang
Journal:  Int J Clin Exp Med       Date:  2014-11-15

3.  Therapy of gallstone disease: What it was, what it is, what it will be.

Authors:  Piero Portincasa; Agostino Di Ciaula; Leonilde Bonfrate; David Qh Wang
Journal:  World J Gastrointest Pharmacol Ther       Date:  2012-04-06

4.  Osteopontin Deficiency Alters Biliary Homeostasis and Protects against Gallstone Formation.

Authors:  Jing Lin; Ming Lu; Wei-Qing Shao; Zong-You Chen; Wen-Wei Zhu; Lu Lu; Hu-Liang Jia; Duan Cai; Lun-Xiu Qin; Jin-Hong Chen
Journal:  Sci Rep       Date:  2016-08-03       Impact factor: 4.379

5.  Osteopontin deficiency protects mice from cholesterol gallstone formation by reducing expression of intestinal NPC1L1.

Authors:  Jing Lin; Wei-Qing Shao; Qing-Zhi Chen; Wen-Wei Zhu; Lu Lu; Hu-Liang Jia; Jin-Hong Chen
Journal:  Mol Med Rep       Date:  2017-06-14       Impact factor: 2.952

6.  Current views on genetics and epigenetics of cholesterol gallstone disease.

Authors:  Agostino Di Ciaula; David Q-H Wang; Leonilde Bonfrate; Piero Portincasa
Journal:  Cholesterol       Date:  2013-04-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.